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The CD8+ T cell response is characterized by generation of a population of effector cells and establishment of
a persistent memory pool. In this issue, Cui et al. (2011) and Siegel et al. (2011) show that cytokine receptor
signaling through the transcription factor STAT3 establishes stable memory CD8+ T cells.Effector CD8+ T cells are important for
immediate pathogen control but are nor-
mally short lived, whereas the memory
population can self renew and is critical
for the recall responses desired for
vaccines—hence there is considerable
interest in determining the factors that
drive these alternative fates. Various
signals are thought to deflect an activated
CD8+ T cell toward the effector versus
memory fate, but cytokines have been
an especially fruitful focus. It has become
clear that inflammatory cytokines, includ-
ing IL-12, type I interferon, and IFN-g,
can enhance generation of effector CD8+
T cells (Cui and Kaech, 2010; Harty and
Badovinac, 2008). Such findings raise
the question of whether a different set
of cytokines promotes the CD8+ T cell
memory fate.
In this issue of Immunity, Cui et al.
(2011) and Siegel et al. (2011) focus on
the transcription factor STAT3, which is
activated by signals from the IL-6, IL-10,
and IL-21 receptors. These cytokines
have varied connotations; IL-6 is associ-
ated with inflammatory responses and
IL-10 is best known for its immunosup-
pressive role, whereas IL-21 is well
characterized for its participation in
CD4+ T cell-B cell collaboration in the
germinal center reaction. These cytokines
also impact CD8+ T cells, including re-
ported effects on CD8+ memory T cell
generation (Yi et al., 2010; Foulds et al.,
2006; Castellino and Germain, 2007), but
it was unclear whether these disparate
studies could be connected. The current
reports suggest that STAT3 activation is
important for sustaining the maintenance
and function of memory CD8+ T cells
(Figure 1).
Cui et al. (2011) use a mouse model in
which the Stat3 gene is conditionally
deleted in activated CD8+ T cells—this
avoids complications of STAT3 deficiencyin other cell types. Although Stat3/
CD8+ T cells make a normal early effector
response and appear to generate an
initial memory pool, the majority of
Stat3/ cells that persist through to the
memory phase have characteristics of
effector, not normal, memory cells. This
includes phenotypic markers, such as
low expression of IL-7Ra and high ex-
pression of the marker KLRG-1, reduced
basal proliferation (a characteristic of
self-renewing memory CD8+ T cells) and
compromised function, including im-
paired protective capacity.
Defining the cytokines that induce
STAT3 activation is a daunting task
because, as discussed, there are at least
three cytokines (IL-6, IL-10, and IL-21) to
consider. However, using mice deficient
in IL-21 and treated with anti-IL-10, Cui
et al. argue that these two cytokines
together could be the major factors. Inter-
pretation of these studies is complex
because systemic loss of IL-21 and IL-
10 signals will affect many cell types, but
these findings form a good foundation
for future studies.
What, then does STAT3 induce when
it’s active? Whereas T-bet and Blimp
have been implicated in CD8+ T cell
effector differentiation, the transcriptional
regulators Eomes and Bcl-6 have been
associated with memory CD8+ T cell
differentiation (Banerjee et al., 2010;
Ichii et al., 2004; Cui and Kaech, 2010;
Rutishauser et al., 2009). Cui et al. show
that expression of both Eomes and
Bcl-6 decline in Stat3/ CD8+ T cells as
they reach the memory phase of the re-
sponse. Bcl-6 (and, confusingly, Blimp-1)
is a direct target of STAT3 (Yoshimura
et al., 2007), but how STAT3 loss influ-
ences Eomes expression is not clear.
Nevertheless, these findings suggest
STAT3-deficient cells fail to induce and/
or maintain expression of transcriptionalImmunity 35, Nregulators that are characteristic of mem-
ory CD8+ T cells.
Additional studies suggest that sup-
pressor of cytokine signaling 3 (SOCS3),
another defined target of STAT3, plays
a role too. SOCS3 acts as an inhibitor of
cytokine receptor signaling including
degradation of IL-6Ra and Jak2 (the latter
being a component of IL-12R signaling).
SOCS3 is expressed at higher levels
in memory-phenotype versus effector
CD8+ T cells, and Cui et al. suggest
that it may ‘‘insulate’’ memory CD8+
T cells, protecting them from inflamma-
tory signals that may derail normal mem-
ory T cell homeostasis.
There are remaining puzzles from
these studies. Kinetic analysis suggests
Stat3/ CD8+ T cells produce a roughly
normal sized memory phenotype pool in
the first month after the LCMV response,
but that in subsequent weeks, the
KLRG-1lo IL-7Rhi pool collapses, whereas
the effector-like population persists.
Because the Stat3 gene is deleted only
with CD8+ T cell activation in this model,
there may be a kinetic delay in complete
loss of STAT3 protein. But perhaps more
likely is that loss of inflammatory cytokine
‘‘insulation’’ may result in erosion (or
phenotypic conversion) of the memory
population. Another surprise was that,
although primed Stat3/ CD8+ T cells
had many traits of ‘‘short-lived effector
cells,’’ they were not short lived: although
there were differences depending on
the exact model used, in some settings
the effector-like Stat3/ cells were main-
tained as efficiently as wild-type memory
cells, resulting in no defect in antigen-
specific cell numbers. Cui et al. note that
these cells have higher Bcl-2 expression
than normal effector cells and propose
that the cells may be sustained by the
very inflammatory cytokine cues that
SOCS3 may normally restrain. Whetherovember 23, 2011 ª2011 Elsevier Inc. 663
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Figure 1. Keeping Memory CD8+ T Cells on Track
Following CD8+ T cell activation and initial proliferation, responding cells face divergent fates. With persistent T cell receptor stimulation and/or inflammatory
cues, the short-lived effector pool is favored. The new studies suggest the production of a stable memory CD8+ T pool involves activation of STAT3 (which,
in this case, may be predominantly induced by IL-10 and IL-21). Active STAT3 induces SOCS3, an inhibitor of various cytokine receptors (including the proin-
flammatory cytokine, IL-12) but STAT3 also promotes expression of Bcl-6, a transcription factor that can enhance memory CD8+ T cell differentiation. In these
ways, STAT3 may reinforce memory CD8+ T cell differentiation as well as insulate the burgeoning memory pool from being diverted into the effector pool. Data
from Siegel et al. indicate that STAT3 could also play a role in the initial expansion of human activated CD8+ T cells.
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spond to a normal population of CD8+
T cells is not yet clear.
A perennial issue in immunology is
whether such in vivo genetic manipulation
studies in mice can be corroborated in
humans. In this case, however, the com-
panion report from Siegel et al. (2011)
reinforces and extends key observations
about the significance of STAT3 in human
CD8+ T cell differentiation. The authors
analyzed a cohort of patients with auto-
somal-dominant Hyper-IgE Syndrome
(AD-HIES), caused by dominant-negative
mutations in STAT3 (typically in the DNA-
binding or SH2 domains of the protein).
AD-HIES patients exhibit a variety of
immune conditions including suscepti-
bility to lung infections and mucocuta-
neous candidiasis (which probably relate
to depressed Th17 cell differentiation)
and increased lymphoma prevalence.
These multiple phenotypes, together
with the limitations of acceptable ex-
periments, put substantial restraints on
what can be determined about the role
of STAT3 in human CD8+ T cell differ-
entiation. However, Siegel et al. make
a number of findings that resonate with
the Cui et al. study. AD-HIES patients
display a decreased frequency and
number of circulating central memory664 Immunity 35, November 23, 2011 ª2011T cells (in both CD4+ and CD8+ T cell pop-
ulations). Furthermore, using in vitro
stimulation assays, Siegel et al. found
that AD-HIES naive T cells exhibited im-
paired capacity to acquire central mem-
ory phenotype as compared to controls.
In keeping with Stat3/ mice, AD-HIES
patient T cells also exhibit reduced ex-
pression of SOCS3 and Bcl-6.
Given the pleiotropic effects of the
dominant-negative STAT3 mutations in
AD-HIES patients, it would be hard to
know whether any of these effects are
intrinsic to the CD8+ T cell pool. However,
a stroke of good luck presented Siegel
et al. with a patient found to be mosaic
for a dominant-negative STAT3 muta-
tion—meaning that some of the subject’s
cells are genetically normal whereas
some carry the STAT3 mutation. Using
PCR analysis, the authors show that
the STAT3 mutant cells are easily de-
tected in B cells and naive T cells but
are virtually absent from memory pheno-
type CD4+ and CD8+ T cells. This prefer-
ential loss of activated STAT3 mutant
cells is mimicked by in vitro stimulation
of T cells.
Siegel et al. provide powerful evidence
for the significance of normal STAT3
function in host protection, by studying
control of natural infections with VaricellaElsevier Inc.zoster virus (VZV) and Epstein-Barr Virus
(EBV). AD-HIES patients have a high inci-
dence of VZV reactivation, and Siegel
et al. find reduced numbers of CD4+
memory T cells that could produce
effector cytokines in response to VZV
antigens. Furthermore, some AD-HIES
patients showed markedly elevated
EBV viral titers and, though absolute
numbers of recirculating EBV-specific
CD4+ and CD8+ T cells appears normal,
the AD-HIES pool has a lower frequency
of central memory phenotype cells.
Whether these effects in AD-HIES
patients are exclusive to dysregulated
T cell memory differentiation will await
further work.
There are some important differences
between the studies from Cui et al. and
Siegel et al. Central memory phenotype
AD-HIES cells showed reduced IL-7R
expression yet had normal or elevated
frequencies of cells in cell cycle—these
trends being in contrast to the Stat3/
mouse cells studied by Cui et al. Interest-
ingly, an impact of the STAT3 mutation
was observed even at the naive T cell
stage in AD-HIES patients, including de-
creased Bcl-6 and SOCS3 gene expres-
sion and in some (but not all) patients an
impaired ability of naive T cells to undergo
initial activation and proliferation when
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et al. deliberately limited deletion of
STAT3 to activated T cells; hence they
were not in a position to address a role
for the factor in the naive pool—but this
is fertile ground for new studies in mice.
Together, these complementary stud-
ies in mice and humans establish an
important role for STAT3 in memory
T cell formation and suggest that cyto-
kines such as IL-10 and IL-21 may be crit-
ical in dictating whether activated T cells
will divert to the effector population or
join the ranks of the functional memory
T cell pool.REFERENCES
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In this issue of Immunity, Choi et al. (2011) analyzed the cellular composition of aortic vessels in normal
and atherosclerotic mice, revealing the presence of conventional CD103+ DCs with a potentially protective
influence on atherosclerosis.Atherosclerosis with its typical complica-
tions of stroke and heart attack continues
to be the primary cause of death in
westernized societies. In this issue of
Immunity, Steinman and colleagues ex-
plore the cellular composition of normal
and atherosclerotic aortic tissue, confirm-
ing the presence of macrophages and
dendritic cells (DCs) of monocyte origin
but also revealing the presence of a
CD103+ DC subset that is developmen-
tally dependent on FMS-like tyrosine
kinase 3 receptor ligand (Flt3L) and is of
nonmonocyte origin (Figure 1). Associa-
tion of this DC population with athero-
sclerotic tissues appears to be protective
and correlates with a relative increase in
regulatory T (Treg) cells.
A simplified view of atherosclerosis en-
visages a sequential model (Libby et al.,
2011), whereby hemodynamic forces im-
pacting on distinct areas of the vascula-
ture, such as the lesser curvature of theaortic arch, result in qualitative changes
to endothelial cells lining these vessels.
Changes include upregulation of adhe-
sion molecules through which circulating
monocytes gain access to the intima, an
area of connective tissue located immedi-
ately below the basement membrane of
the endothelium (Figure 1). Endothelial
dysfunction also affects vessel wall per-
meability, promoting uptake and reten-
tion of circulating lipids, such as choles-
terol-containing low-density lipoproteins
(LDLs). These fatty particles are engulfed
by monocyte-derived macrophages that
eventually become engorged to his-
tologically appear as ‘‘foam cells’’ (Lusis,
2000). The crystalline nature of some of
these deposits not only makes their elim-
ination by macrophages difficult, but also
evokes inflammasome activation and the
secretion of proinflammatory cytokines.
The consequence of this inflammatory
response is swelling of the intimal space,perpetuation of endothelial dysfunction,
further recruitment of leukocytes, and
exacerbation of hemodynamic stress
due to bulging of the lesion into the vessel
lumen. When the endothelial lining even-
tually ruptures, platelet activation and
thrombus formation lead to the charac-
teristic atherosclerotic lesions that can
either occlude the vessel lumen locally
or, upon dislodgement, block distant
arteries.
Atherosclerosis is not only a critical
medical concern, but represents an in-
teresting disease for immunologists to
study basic mechanisms of localized in-
flammation. Although atherosclerosis is
associated with intimal immigration of
a variety of leukocytes, including mono-
cytes, DCs, T cells, B cells, and mast
cells, it is widely believed that monocyte-
derived macrophages are the dom-
inant phagocytic cell type involved in the
pathogenesis of this disease. Buildingovember 23, 2011 ª2011 Elsevier Inc. 665
